DUBLIN–(BUSINESS WIRE)–The “Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The global bone cancer diagnosis and therapeutics market is growing at a considerable CAGR of 8.1%
Rising number of incidences in individual related to Paget disease is one of the prime factors affecting and driving the market. Increasing per capita healthcare expenditure, technology for stem cell transplants among others is also estimated to be the key factors that are contributing significantly towards the growth of the market.
However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.
However, R&D and technological advancement are some of the key factors that are creating opportunities for the market. New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market.
For instance, in November 2020, BeiGene had officially notified the approval in China for its XGEVA (denosumab). This approval was received in China for the patients suffering due to bone metastasis from solid tumors along with patients having multiple myeloma in order to prevent skeletal-related events.
Based on the type, primary bone cancer holds significant share in the market. It is a type of cancer that occurs and begins in the bone. It may occur to the patient on the surface, in the outer layer or it can be observed from the center of the bone. The treatment is very necessary if it is left untreated it can spread to other body parts.
Further, According to Australian institute of health and wealth around 250 Australians every year are been diagnosed with primary bone cancer. More than 30 types of bone cancer are considered in this category; however most commonly observed includes Osteosarcoma, Chondrosarcoma and Ewing’s sarcoma. This can be treated through surgery and various type of therapy given to patients.
Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing number of cancer patients along with growing geriatric population is likely to drive the growth of the regional market. Further, due to health availability, rising health care expenditure along with rising number of market player in India, China and South Korea are also some of the factors that are affecting and impacting the growth.
Market Player Outlook
Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. To survive in the market, these players adopt different marketing strategies such as product launches and acquisition.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global bone cancer diagnosis and therapeutics market based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where in the market.
Market Segmentation
Global Laboratory Centrifuge Market by Product Type
- Devices
- Microcentrifuge
- Multipurpose Centrifuge
- Floor-Based Centrifuge
- Ultracentrifuge
- Accessories (Tubes, Centrifuge Bottles, Buckets, Plates)
Global Laboratory Centrifuge Market by Application
- Diagnostic
- Microbiology
- Genomics
- Proteomics
- Blood Component Separation
- Others (Cellomics)
Global Laboratory Centrifuge Market by End-Users
- Hospitals
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
Company Profiles
- Amgen Inc.
- Bayer AG
- Bristol-Myers Squibb Co.
- BeiGene
- Eli lilly and company
- F. Hoffmann-la roche ltd.
- Infinity Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Koninklijke Philips N.V.,
- Merck & Co., Inc.
- Merrion pharmaceuticals plc.
- Novartis AG
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/wn2hnp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900